Last10K.com

Amphastar Pharmaceuticals, Inc. (AMPH) SEC Filing 10-Q Quarterly report for the period ending Sunday, March 31, 2019

Amphastar Pharmaceuticals, Inc.

CIK: 1297184 Ticker: AMPH

EXHIBIT 99.1

 

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2019

 

Reports Net Revenues of $79.8 Million for the Three Months Ended March 31, 2019

 

RANCHO CUCAMONGA, CA – May 9, 2019 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended March 31, 2019.

 

First Quarter Highlights

 

·

Net revenues of $79.8 million for the first quarter

·

GAAP net income of $0.9 million, or $0.02 per share, for the first quarter

·

Adjusted non-GAAP net income of $4.9 million, or $0.10 per share, for the first quarter

 

Dr. Jack Zhang, Amphastar’s Chief Executive Officer, commented:  “We are very pleased with the strong sales growth in the quarter and believe that increased promotion of Primatene® Mist and potential additional generic approvals this year will help us achieve strong sales growth for 2019.”

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

 

March 31, 

 

 

2019

 

2018

 

 

(in thousands, except per share data)

Net revenues

    

$

79,790

    

$

58,393

GAAP net income (loss) attributable to Amphastar

 

$

868

 

$

(7,141)

Adjusted non-GAAP net income (loss) attributable to Amphastar*

 

$

4,885

 

$

(2,513)

GAAP diluted EPS attributable to Amphastar shareholders

 

$

0.02

 

$

(0.15)

Adjusted non-GAAP diluted EPS attributable to Amphastar shareholders*

 

$

0.10

 

$

(0.05)


The following information was filed by Amphastar Pharmaceuticals, Inc. (AMPH) on Thursday, May 9, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Amphastar Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Amphastar Pharmaceuticals, Inc..

Continue

Assess how Amphastar Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Amphastar Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

Tools

Rating

Learn More
Bullish Bearish Neutral
Filter by Sentiment:
All
Positive
Negative
Filter by Category:
All
Financial
Revenue
M & A
Other
Filter by Subcategory:
All
Expense
Product
Cash Flow
Other
Inside Amphastar Pharmaceuticals, Inc.'s 10-Q Quarterly Report:

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows
Condensed Consolidated Statements Of Comprehensive Income (Loss)
Condensed Consolidated Statements Of Operations
Accounts Payable And Accrued Liabilities
Accounts Payable And Accrued Liabilities (Details)
Accounts Payable And Accrued Liabilities (Tables)
Commitments And Contingencies
Commitments And Contingencies (Collaboration Agreements) (Details)
Commitments And Contingencies (Future Minimum Rental Payments) (Details)
Commitments And Contingencies (Lease Cash Flow Information) (Details)
Commitments And Contingencies (Lease Expense) (Details)
Commitments And Contingencies (Other Information To Leases) (Details)
Commitments And Contingencies (Purchase Commitments) (Details)
Commitments And Contingencies (Tables)
Customer And Supplier Concentration
Customer And Supplier Concentration (Details)
Customer And Supplier Concentration (Tables)
Debt
Debt (Narrative) (Details)
Debt (Schedule Of Debt) (Details)
Debt (Tables)
Employee Benefits
Employee Benefits (Details)
Fair Value Measurements
General
Goodwill And Intangible Assets
Goodwill And Intangible Assets (Summary Of Changes In The Carrying Amount Of Goodwill) (Details)
Goodwill And Intangible Assets (Summary Of Intangible Assets) (Details)
Goodwill And Intangible Assets (Tables)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Calculation Of Basic And Diluted Net Income (Loss) Per Share) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Narrative) (Details)
Income (Loss) Per Share Attributable To Amphastar Pharmaceuticals, Inc. Shareholders (Tables)
Income Taxes
Income Taxes (Summary Of Income Before Taxes) (Details)
Income Taxes (Tables)
Inventories
Inventories (Details)
Inventories (Tables)
Litigation
Litigation (Details)
Property, Plant, And Equipment
Property, Plant, And Equipment (Summary Of Property, Plant, And Equipment) (Details)
Property, Plant, And Equipment (Tables)
Related-Party Transactions
Related-Party Transactions (Details)
Revenue Recognition
Revenue Recognition (Analysis Of Product Return Liability) (Details)
Revenue Recognition (Analysis Of The Chargeback Provision) (Details)
Revenue Recognition (Tables)
Segment Reporting
Segment Reporting (Selected Financial Information By Reporting Segment) (Details)
Segment Reporting (Summary Of Net Revenues By Product Segment) (Details)
Segment Reporting (Summary Of Revenues And Long-Lived Assets By Geographic Region) (Details)
Segment Reporting (Tables)
Stockholders' Equity
Stockholders' Equity (2014 Employee Stock Purchase Plan) (Details)
Stockholders' Equity (Equity Awards To Consultants And Advisory Board Members) (Details)
Stockholders' Equity (Information Relating To Option Grants And Exercises) (Details)
Stockholders' Equity (Information Relating To Rsu Grants And Deliveries) (Details)
Stockholders' Equity (Key Assumptions Used In Determining Fair Value Of Options Granted) (Details)
Stockholders' Equity (Restricted Stock Units) (Details)
Stockholders' Equity (Share Buyback Program) (Details)
Stockholders' Equity (Share-Based Compensation Expense Included In The Statement Of Operations) (Details)
Stockholders' Equity (Summary Of Nonvested Options) (Details)
Stockholders' Equity (Summary Of Option Activity) (Details)
Stockholders' Equity (Summary Of The Changes In Stockholders' Equity) (Details)
Stockholders' Equity (Tables)
Stockholders' Equity (The 2015 Equity Incentive Plan) (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Details)
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Recent Accounting Pronouncements) (Details)
Ticker: AMPH
CIK: 1297184
Form Type: 10-Q Quarterly Report
Accession Number: 0001297184-19-000027
Submitted to the SEC: Thu May 09 2019 3:34:45 PM EST
Accepted by the SEC: Fri May 10 2019
Period: Sunday, March 31, 2019
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/amph/0001297184-19-000027.htm